Clinical trialNCT00090987CompletedPhase 2Interventional

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

SponsorAIDS Malignancy ConsortiumEnrollment30Sarcoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with HIV-related Kaposi's sarcoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Ariela Noy, MD
Memorial Sloan Kettering Cancer Center
Study Chair
clinicaltrials.gov ↗
Henry Koon, MD
Beth Israel Deaconess Medical Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moores Ucsd Cancer Center
La Jolla, California, United States
Jonsson Comprehensive Cancer Center at Ucla
Los Angeles, California, United States
Usc/norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States
Desert Regional Medical Center Comprehensive Cancer Center
Palm Springs, California, United States
Ucsf Comprehensive Cancer Center
San Francisco, California, United States
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, United States
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Siteman Cancer Center at Barnes-Jewish Hospital
St Louis, Missouri, United States
Memorial Sloan - Kettering Cancer Center
New York, New York, United States
Albert Einstein Cancer Center at Albert Einstein College of Medicine
The Bronx, New York, United States
Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Joan Karnell Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Imatinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2005
Primary completion: 31 Dec 2009
Completion: 31 Dec 2009
Last update posted: 6 Jun 2018
Registered enrollment: 30
Registry id: NCT00090987

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.